User menu

Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963.

Bibliographic reference Levi, F ; Humblet, Yves ; Gorlia, Thierry ; Tubiana, N ; Smaaland, R ; et. al. Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963..41st Annual Meeting of the American-Society-of-Clinical-Oncology (Orlando (Fl), May 13-17, 2005). In: Journal of Clinical Oncology, Vol. 23, no. 16, p. 267S-267S (2005)
Permanent URL http://hdl.handle.net/2078.1/60904